COVID-19 induces coagulopathy manifested as elevation of dimerized plasmin fragment D (D-dimer) levels.
1-5 As a result, patients with COVID-19 frequently experience both arterial thromboembolism (ATE) and venous thromboembolism (VTE). Bourguignon et al
6 reported that pulmonary embolism and deep vein thrombosis occurred in 20.6% to 49.0% of patients with COVID-19 managed in intensive care units (ICUs). In many facilities, high-risk patients with COVID-19 are given anticoagulation (AC) at doses higher than the prophylactic dose for primary prophylaxis of VTE during their hospitalization.
7-9 AC treatment in patients hospitalized with COVID-19 is associated with reduced mortality.
10-12 Of note, the risk of ATE and VTE in patients with COVID-19 extends beyond their hospitalization. These thrombotic events are associated with readmission and mortality 90 days after discharge from the index admission. To mitigate the risk of VTE, a short-term course of AC has been used in patients with COVID-19 after their hospital discharge. This practice, however, is challenged by the low incidence of VTE in unselected patients with COVID-19. Giannis et al
13 reported that 1.55% of patients with COVID-19 experienced VTE within 90 days after discharge. Universal prescription of postdischarge AC in patients with COVID-19 offers marginal clinical benefits and may cause harm in patients at high risk of bleeding. Given the unclear evidence, clinicians are facing the dilemma of which patients hospitalized with COVID-19 could benefit from postdischarge AC. We conducted a cohort study of patients with COVID-19 discharged from an inpatient hospital stay to assess the rate of postdischarge thrombosis in patients with COVID-19, identify the factors associated with the risk of postdischarge VTE, and evaluate the association of postdischarge AC use with VTE incidence.